Clinical / Pharmaceutical

Desmopressin

DDAVP · Minirin · 1-desamino-8-D-arginine vasopressin

Desmopressin (DDAVP) is a highly engineered, synthetic evolution of the endogenous human antidiuretic hormone (Vasopressin). Through precise amino acid substitution, its antidiuretic potency is massively magnified while its dangerous vasoconstrictive properties are entirely eliminated. Clinically, it is the absolute gold standard to aggressively halt catastrophic fluid loss in central diabetes insipidus, treat severe surgical bleeding disorders (Hemophilia A), and manage nocturnal enuresis.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: August 2026Evidence: High1 peer-reviewed citation
Typical research dose
10-40 mcg/day (intranasal) or 0.1-0.4 mg oral
Frequency
1-3× daily
Half-life
~1.5-2.5 hours
Common vials
N/A (oral)
CAS
16679-58-6
Molecular weight
1069.2 g/mol

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Sexual / hormonal2/10

    Not a sex peptide. Listed because peptide libraries get the search. Labeled jobs are diabetes insipidus, nocturia, bleeding disorders - clinician territory.

Compound card

Class
Synthetic vasopressin analog (DDAVP; labeled antidiuretic)
Formula
C46H64N14O12S2
Status
Not FDA-approved · research use

How it works

Desmopressin (DDAVP) is a synthetic analog of the endogenous antidiuretic hormone arginine vasopressin (AVP). By modifying AVP - deaminating the N-terminus and substituting D-arginine for L-arginine - developers increased its antidiuretic potency while almost completely eliminating the vasopressor (blood pressure-raising) effect.

It acts selectively on V2 receptors in the renal collecting ducts, increasing water reabsorption and concentrating urine. It is widely used to treat diabetes insipidus, severe bedwetting, and mild hemophilia A (by releasing von Willebrand factor).

Source: PMID: 3527577

Background & History

Desmopressin (DDAVP) is among the most widely prescribed peptide drugs globally. Developed in 1967 by modifying natural vasopressin, it solved the problem of vasopressin's short half-life and blood pressure effects. Used daily by millions of patients with diabetes insipidus and nocturnal enuresis. Also used pre-operatively in mild hemophilia A to boost factor VIII levels without transfusion.

Research Use Cases

  • ✓Central diabetes insipidus
  • ✓Nocturnal enuresis
  • ✓Hemophilia A
  • ✓Von Willebrand disease Type 1

Dosing

PhaseDoseFrequencyNotes
Standard Dose (Oral)100 - 200 mcg1-3x dailyFDA-approved for diabetes insipidus. Often taken at bedtime for nocturia/enuresis.

Administration

Route / form
Oral tablets, sublingual melt, or intranasal spray
Timing
Usually at bedtime for enuresis.
Empty stomach?
No - Food timing is not critical.

Timeline

Acute (1-2 hours)
Significant decrease in urine output and increase in urine osmolality.

Who it is for

Diabetes Insipidus / Nocturia

High

Gold-standard therapeutic for central diabetes insipidus and primary nocturnal enuresis.

Safety & Considerations

FDA-approved. Major risk is hyponatremia (water intoxication) due to fluid retention. Fluid intake must be restricted when taking DDAVP. Not for use in individuals with heart failure or uncontrolled hypertension.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • Fluid restriction rules are on the label. This site will not dose DDAVP.
  • Not vasopressin (arginine vasopressin) and not oxytocin.

Verdict

Desmopressin is DDAVP. Hyponatremia kills people who play with this. It is not a gym peptide. This page is identity, not a bedwetting or hemophilia protocol.

Interactions & Contraindications

Avoid concurrent NSAIDs (increase ADH effect/hyponatremia risk). Carbamazepine, chlorpropamide, and SSRIs may potentiate antidiuretic effect. Restrict fluid intake during use.

Synergies & Common Stacks

+ Vasopressin →

Desmopressin is the synthetic, clinically superior analogue of vasopressin - they are never combined but represent the same receptor pathway.

Frequently Asked Questions

How is desmopressin different from vasopressin?▼
Vasopressin raises blood pressure (V1 receptors) and retains water (V2 receptors). Desmopressin is modified to specifically target V2 receptors, retaining water without dangerously elevating blood pressure.

References

  1. Richardson DW, Robinson AG “"Desmopressin: a review of its use in diabetes insipidus".” Annals of Internal Medicine (1985). PMID: 3896088

Looking for a trusted source? See our recommended suppliers

Independently tested · COA-verified · Save 10% with our exclusive code

See suppliers →
← Back to Peptide Library